Development of an Anti-GM-CSF Antibody for Treatment of Rheumatoid Arthritis

开发用于治疗类风湿性关节炎的抗 GM-CSF 抗体

• 批准号: nhmrc : 381407
• 负责人: A/Pr Geoffrey Mccoll
• 金额: $ 18.87万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-an-anti-rheumatoid-arthritis/95174
• 关键词: Development; Anti; GM; CSF; Antibody

The aim of this project is to develop assays for the evaluation of the efficacy and safety of an anti-GMCSF neutralizing antibody in a Australian first-in-man clinical trial in patients with severe rheumatoid arthritis (RA). This chimeric antibody has been developed by the Ludwig Institute for Cancer Research, Melbourne Branch, in conjunction with KaloBios Pharmaceuticals, Inc., USA. It is intended to use the assays developed in this project to facilitate commercial development of this antibody, and result in the development of an improved treatment for this devastating disease.

该项目的目的是开发一种分析方法，用于在澳大利亚对严重类风湿关节炎(RA)患者进行的首例人临床试验中评估抗GMCSF中和抗体的有效性和安全性。这种嵌合抗体由路德维希癌症研究所墨尔本分部与美国KaloBios制药公司联合开发。它的目的是利用在这个项目中开发的检测方法来促进这种抗体的商业开发，并导致开发一种改进的治疗这种毁灭性疾病的方法。